title: Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study.
abstract: To assess the effects of early initiation of antiretroviral therapy on cell-free and cell-associated viral load in blood and lymphoid tissue, we performed a randomized, open-label, multicenter trial comparing a double (zidovudine + lamivudine) and triple (zidovudine + lamivudine + ritonavir) drug combination in treatment-naive, asymptomatic patients with CD4 counts >400 cells/microl. HIV-1 RNA was measured in plasma, peripheral blood mononuclear cells, and sequential tonsil or lymph node biopsies (27 patients); the study follow-up was 2 years. Among 42 randomized patients, the proportion with plasma HIV-1 RNA <50 copies/ml was 16% and 74% at week 24 (p<.001) in those randomized to double and triple therapy, respectively, necessitating frequent treatment intensification in the double arm. After a rapid decline within 4 weeks in both arms, cell-associated HIV-1 RNA decreased further only in those patients with sustained suppression of plasma viral load, but remained almost always detectable at low levels, indicating persisting transcription of viral RNA. CD4 counts increased by 200 to 250 cells/microl at week 96 in both arms without significant differences (intent-to-treat analyses). Thus, even if treatment is initiated early in asymptomatic patients with preserved CD4 counts, three drugs are necessary to achieve sustained decreases of HIV load in blood and lymphoid tissue.
authors.affiliation: Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland. Milos.Opravil@dim.usz.ch
authors.forename: M
authors.initials: M
authors.lastname: Opravil
authors.forename: R W
authors.initials: RW
authors.lastname: Cone
authors.forename: M
authors.initials: M
authors.lastname: Fischer
authors.forename: P L
authors.initials: PL
authors.lastname: Vernazza
authors.forename: S
authors.initials: S
authors.lastname: Bassetti
authors.forename: P
authors.initials: P
authors.lastname: Lorenzi
authors.forename: L R
authors.initials: LR
authors.lastname: Bisset
authors.forename: P
authors.initials: P
authors.lastname: Ott
authors.forename: W
authors.initials: W
authors.lastname: Huber
authors.forename: M C
authors.initials: MC
authors.lastname: Knuchel
authors.forename: M
authors.initials: M
authors.lastname: Roos
authors.forename: R
authors.initials: R
authors.lastname: Lüthy
authors.forename: R
authors.initials: R
authors.lastname: Weber
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008221:Lymphoid Tissue / Q000821:virology; D008297:Male; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use*; D013997:Time Factors; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019438:Ritonavir